Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion

Jaguar Health (NASDAQ:JAGX), a commercial-stage pharmaceutical company focused on gastrointestinal products, released its consolidated financial results for the fourth quarter and full year ended December 31, 2025, on April 7, 2026.

Leia mais: Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion
Grafa

FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).

Leia mais: FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010
Grafa

Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology

Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.

Leia mais: Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology
Grafa

Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001

Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.

Leia mais: Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001
Grafa
Technology

Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions

Booz Allen Hamilton (NYSE:BAH) announced on April 7, 2026, the successful completion of its acquisition of Defy Security, a move aimed at consolidating its position as a dominant provider of high-speed, tech-enabled cybersecurity services for both commercial and government sectors.

Leia mais: Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions
Grafa
Technology

ASML shares fall as U.S. lawmakers propose further curbs on China exports

Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.

Leia mais: ASML shares fall as U.S. lawmakers propose further curbs on China exports
Grafa

NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury

NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.

Leia mais: NervGen Pharma secures FDA alignment for Phase 3 registrational trial in spinal cord injury